Objectives: Although suprarenal fixation may be of benefit during endovascular aneurysm repair (EVAR), its safety with regards to renal effects remains uncertain. To date, there has been no controlled study of the topic, with most reports relying upon single-center experiences that use heterogeneous patient populations and devices from different manufacturers. The purpose of this analysis was to evaluate the effect of suprarenal fixation on renal function by comparing homogeneous patient populations receiving EVAR grafts from a single manufacturer that are identical in design and delivery method, except for utilizing either suprarenal (SR) or infrarenal (IR) fixation. Since the first description of endovascular abdominal aortic aneurysm repair (EVAR) in 1991 by Parodi, Palmaz, and Barone, 1 the use of this technique has become widespread. With increased acceptance by clinicians and patients, EVAR is rapidly overtaking open repair as the predominant form of repair for abdominal aortic aneurysms. However, despite the enthusiasm for this approach, one third of all patients remain ineligible for these grafts. Furthermore, over half of patients at highest risk for surgery and who would benefit most fail to qualify. The limitations of endovascular repair are largely due to anatomic constraints, including proximal fixation inadequacies and small delivery vessels.
Since the first description of endovascular abdominal aortic aneurysm repair (EVAR) in 1991 by Parodi, Palmaz, and Barone, 1 the use of this technique has become widespread. With increased acceptance by clinicians and patients, EVAR is rapidly overtaking open repair as the predominant form of repair for abdominal aortic aneurysms. However, despite the enthusiasm for this approach, one third of all patients remain ineligible for these grafts. Furthermore, over half of patients at highest risk for surgery and who would benefit most fail to qualify. The limitations of endovascular repair are largely due to anatomic constraints, including proximal fixation inadequacies and small delivery vessels. 2 Although advances that come with new device development seek to solve these issues, proximal neck angulation and length continue to be limiting factors.
Despite the suggestion of recent randomized trials that the risk associated with EVAR is less than standard open repair, concerns regarding EVAR durability remain. 3, 4 The development of late graft migration and endoleaks occurs in up to 30%, 5, 6 and are most likely responsible for the persistent risk of aneurysm rupture occurring in up to 1% annually after EVAR. 5, 7 Suprarenal fixation with bare wire stents has been proposed as a method for improving proximal fixation, thus allowing endovascular repair of aneurysms with complex neck morphology or short proximal necks. Furthermore, creation of a more stable proximal fixation may lead to a decrease in late complications, including graft migration, endoleak formation, and aneurysm rupture.
The risk of crossing the renal vessels remains uncertain, however. Because of the nature of EVAR, these patients are already at considerable risk for developing renal complications. In addition, many patients have diabetes mellitus or renal insufficiency, making them at even higher risk. Renal insufficiency after EVAR may be as high as 20%, and the causes are likely multifactorial, including a combination of contrast, mechanical, and atheroembolic sources. 8 Preoperative evaluation routinely exposes patients to contrast dye during computed tomography (CT) or, less commonly, catheter angiography.
In addition, during placement, self-expanding grafts are often partially deployed in the suprarenal position and then pulled down the aorta into the final position, potentially dislodging aortic debris and resulting in atheroemboli into the renal vessels. In fact, renal infarction rates as high as 19% have been documented during EVAR. 9 Many devices also use balloon fixation of the proximal graft that may temporarily occlude the renal vessels, potentially resulting in thrombosis, embolus, or dissection. The safety of then placing a bare wire stent across the renal vessels is concerning.
Although the effect of suprarenal fixation with bare stents has been investigated, most studies had included small patient populations and have yielded limited conclusive data. [10] [11] [12] [13] [14] [15] To date, there has been no controlled study of the topic. Most published reports compare devices of different configurations, materials, and deployment strategies, making it even more difficult to come to any sound conclusion. 9, [16] [17] [18] [19] [20] In addition, many of these studies have used custom-made devices. With the availability of next generation and commercially available US Food and Drug Administration (FDA)-approved devices, these comparisons are now obsolete.
The purpose of this comparative analysis was to evaluate the effect of suprarenal fixation on renal function by comparing homogeneous patient populations receiving EVAR grafts from a single manufacturer that are identical in design and delivery method, except for utilizing either suprarenal or infrarenal fixation.
METHODS
Two hundred eighty-three patients underwent EVAR with the Powerlink (Endologix, Inc, Irvine, Calif) unibody bifurcated graft in the setting of two pivotal, multicenter FDA trials. Data collected during these trials was retrospectively reviewed. The inclusion and exclusion criteria were identical for each trial (Table I) . Except for fixation scheme, suprarenal or infrarenal, the endografts are identical in design (Fig 1) , which has been described in detail previously. 21 The main body of the endoskeleton consists of a single 0.016-inch wire constructed of a cobalt chromium alloy that is woven into a double spine, without joints or welds. The suprarenal fixation component incorporates a bare cage portion 22 mm in length consisting of six wire segments along the circumference and is a continuation of the endoskeleton. It does not use barbs or hooks, but relies on radial force for proximal fixation. Both grafts use identical delivery methods.
For each patient, baseline demographic data, blood pressure, and serum creatinine levels were recorded upon enrollment. Postoperative monitoring consisted of a physical examination, blood pressure measurement, and CT angiography at 1, 6, and 12 months, and then annually. Serum creatinine (SCr) levels were obtained at the discretion of the treating physician early in the trials and have been subsequently incorporated into the routine surveillance during the suprarenal trial. For comparison of the immediate and delayed effects of suprarenal fixation on renal function, each group was subdivided into preoperative, perioperative (1 to 7 days), or postoperative (Ͼ7 days) groups. To compensate for weight and age differences, creatinine clearance (CrCl) for each time period was calculated using the Cockcroft-Gault formula: CrCl ϭ (140 -age) ϫ weight/(SCr ϫ 72). To adjust for female gender a multiplication factor of 0.85 was applied. 22 Complete SCr and postoperative CT data were available in 147 of 192 (77%) IR patients and in 79 of 91 (87%) SR patients. These patients were used for data analysis.
Baseline renal insufficiency was defined as a preoperative SCr Ͼ1.5 mg/dL. Renal impairment was defined as an increase in SCr Ͼ30% and an absolute value Ͼ1.5 mg/dL or the need for hemodialysis. Adverse renal events were determined by CT and clinical chart review and included the presence of renal infarction, progressive renal artery stenosis, renal stent placement, and renal artery occlusion.
Data analysis. Data were expressed as mean and standard deviation. Comparison of continuous variables was made by using the Student's t test for independent variables. Categoric variables were compared with the Fisher's exact test. Differences were considered significant if the two-tailed P value was Ͻ0.05.
RESULTS

Demographics.
The IR and SR groups were well matched (Table II) . There was no statistically significant difference between groups in the prevalence of comorbid conditions. Mean follow-up was 11.9 Ϯ 14.9 months for IR fixation and 7.3 Ϯ 8.9 months for SR fixation. The volume of contrast delivered intraoperatively was 186 Ϯ 83 mL for IR and 182 Ϯ 79 mL for SR fixation and was similar between groups (P ϭ .770) ( Table III) . The perioperative 30-day mortality was also similar for IR and SR fixation at 1.4% and 0% (P ϭ .543).
Creatinine and creatinine clearance. Mean SCr decreased during the perioperative period with both IR (1.12 Ϯ 0.31 mg/dL to 1.08 Ϯ 0.45 mg/dL, P ϭ 0.269) and SR (1.13 Ϯ 0.30 mg/dL to 1.06 Ϯ 0.28 mg/dL, P ϭ .06) fixation, although the differences did not reach statistical significance (Table IV) . Comparison of postoperative SCr with preoperative levels revealed that mean SCr increased significantly in IR (1.33 Ϯ 0.71 mg/dL, P Ͻ .0001) and SR groups (1.26 Ϯ 0.34 mg/dL, P ϭ .002). There were no significant differences in SCr between IR and SR groups during the preoperative (P ϭ .893), perioperative (P ϭ .607), or postoperative (P ϭ .344) periods.
To determine whether the elevation in SCr was durable, a subgroup analysis was performed for those patients with follow-up of Ͼ12 months. In this population of 27 SR and 67 IR patients, SCr remained significantly elevated from baseline with IR (1.28 Ϯ 0.63 mg/dL, P ϭ .001) and SR (1.24 Ϯ 0.31 mg/dL, P ϭ .047) fixation; however, it was not significantly different between groups. A similar pattern was noted when changes in CrCl were compared, further confirming the alterations in renal function seen with SCr (Table IV) .
Renal impairment occurred in 15 IR patients (10.2%) and six SR patients (7.6%), which was not statistically different (P ϭ .634) (Table III) . There were no differences in the volume of intraoperative contrast delivered among those who developed renal impairment and those who did not in IR (186 Ϯ 83 vs 184 Ϯ 86 mL, P ϭ .952) or SR (182 Ϯ 79 vs 130 Ϯ 56 mL, P ϭ .150) groups. Hemodialysis was required in one patient (0.7%) who had received a graft utilizing IR fixation, with no significant difference between groups (P ϭ 1.00).
Preoperative renal insufficiency has been associated with worse outcomes. 10, 17, 18 To investigate this in our patient population, a subgroup analysis of patients with preoperative renal insufficiency (SCr Ͼ1.5 mg/dL) was performed. No patients in the SR group developed postoperative renal impairment, but four IR patients (26.7%) had. This difference was not statistically significant (P ϭ .263) (Table III) .
Renal events. Adverse renal events occurred in 10 patients (6.8%) with IR fixation compared with three (3.8%) with SR fixation (Table III) . This difference was not statistically significant (P ϭ 0.550). In the IR group, three patients required stent placement, one for progressive renal artery stenosis and two for partial coverage of the renal artery from graft malpositioning during EVAR (Table V, online only). Renal infarction was noted in four patients with IR fixation, three occurring in the early postoperative period, one of which was due to the intentional intraoperative coverage of the accessory renal artery. Renal artery occlusion occurred in three IR patients between 6 and 12 months postoperatively, all of which were in accessory renal arteries; only one resulted in radiographically significant infarction. The SR patients had three events: two were progressive stenoses being followed without intervention, and one patient required a renal artery stent during EVAR (Table IV) . During the perioperative period, both IR and SR patients had significant decreases in SBP and DBP. Over the long term, however, SBP returned to baseline, and there was no significant difference in either IR (140 Ϯ 22 mm Hg to 139 Ϯ 18 mm Hg, P ϭ .359) or SR (141 Ϯ 20 mm Hg to 141 Ϯ 16 mm Hg, P ϭ .986) groups compared with preoperative values. Similar changes were seen with DBP in IR (78 Ϯ 11 mm Hg to 77 Ϯ 11 mmHg, P ϭ .329) and SR (77 Ϯ 11 mm Hg to 77 Ϯ 10 mm Hg, P ϭ .819) patients. There were no statistically significant differences in SBP or DBP between IR and SR patients during the preoperative (SPB, P ϭ .817; DBP, P ϭ .429), perioperative (SBP, P ϭ .994; DBP, P ϭ .352), or postoperative (SBP, P ϭ 0.270; DBP, P ϭ .831) periods.
DISCUSSION
Endovascular abdominal aortic aneurysm repair is gaining widespread popularity among the medical and lay communities. Despite the heightened interest in this technique, up to one third of all patients remain ineligible, as do half of those at highest risk for open repair. Recent studies have confirmed that the perioperative risk of EVAR is less than with standard open repair, 3,4,6 but concerns regarding durability and long-term safety remain. [5] [6] [7] The development of endoleaks or graft migration occurs in up to 30%, most of which occur as a result of failure at the proximal fixation site. 5, 6, 23, 24 Several factors likely contribute to these failures. Whereas the suprarenal aorta remains stable in diameter, the proximal infrarenal neck dilates over time after EVAR, weakening the seal in this area. 23, 25, 26 In addition, short proximal aortic necks 24 and Ͼ40° angulation 27 have been implicated in graft migration and endoleak formation.
Suprarenal fixation by using bare stents has been proposed to increase patient eligibility and prevent late complications. Recent data with long-term follow-up suggest that SR fixation decreases late graft migration and endoleak formation 26 and may prevent complications due to aortic neck angulation. 28 The impact of crossing the renal vessels with stents is uncertain, however.
Studies using in vitro and animal models have shown that a reduction in flow or vessel area may result, especially in the presence of more than one stent strut crossing the orifice 29 or the development of neointimal hyperplasia on the stent struts. 30 Further, Birch et al 31 established in the porcine model that stent configuration and the material from which the stent is constructed may also significantly affect renal outcomes.
Data to suggest the safety of suprarenal fixation during EVAR have been accumulating but have not been conclusive (Table VI) . These studies show that postoperative renal dysfunction occurs in 2.6% to 29.9% of patients after EVAR with SR fixation. [10] [11] [12] [13] [14] [15] 17, 18, 20, [32] [33] [34] In those studies that compared SR results with IR fixation, most have demonstrated no significant difference between the two types of fixation for the development of postoperative renal dysfunction. 15, 18, 20 In one of the larger studies, however, Alric et al 17 showed in 169 patients with an 18-month follow-up that postoperative renal impairment occurred in 17.2% of SR patients, which was significantly worse than the IR group (16.4%) (P ϭ .04).
The development of adverse renal events, including renal infarction, stenosis, or renal artery occlusion, occurs in 2.1% to 19% of patients after EVAR with SR fixation. [9] [10] [11] [12] [13] [14] [15] [16] 18, 19, [32] [33] [34] Although most studies failed to detect a significant difference between SR and IR fixation, 15, 16, 18, 19, 33 Bockler et al 9 reviewing their data on 202 patients who underwent EVAR with SR fixation, with a mean follow-up of 37 months, demonstrated that 39 patients (19%) developed renal infarction in the SR group compared with 17 in the IR group (3.7%) (P Ͻ .00001).
In addition to conflicting results arising from two of the larger studies to date, most published reports have included small patient numbers from single-center experiences, mak- ing it difficult to come to any solid conclusions. Furthermore, these reports have typically evaluated data from multiple endografts that are very different in materials, design, and deployment technique, making these comparisons even less optimal. Unlike previous studies, the present study compares grafts that are identical except for fixation technique (Fig) . The SR and IR groups were well matched, attesting to the similarities in the selection process for each trial (Table II) . The prevalence of comorbid conditions, including coronary artery disease, baseline renal insufficiency, diabetes mellitus, and hypertension, were similar to previously reported series. 15, 18 In this study, SCr improved in both the SR and IR groups in the immediate perioperative period, likely representing the aggressiveness with which these patients were hydrated in an effort to minimize contrast nephropathy. With long-term follow up, however, both groups developed progressive renal dysfunction compared with the preoperative levels. Mean SCr significantly increased with both IR (1.12 Ϯ 0.31 mg/dL to 1.33 Ϯ 0.71 mg/dL, P Ͻ .0001) and SR (1.13 Ϯ 0.30 mg/dL to 1.26 Ϯ 0.34 mg/dL, P ϭ .002) fixation (Table IV) . There were no differences in SCr between SR and IR fixation during any time period. An identical trend in renal function was noted after compensating for weight, age, and gender by calculating the CrCl, further validating the findings of progressive renal dysfunction in both groups (Table IV) .
These findings are consistent with previous reports 15, 19, 20 that also showed decline of renal function over time. Alsac et al 20 recently published their data comparing the Zenith (Cook Diagnostic, Bloomington, IN) and Talent (World Medical Manufacturing Corp, Sunrise, Fla) devices with the AneuRx device (Medtronic, Santa Rosa, Calif) in 137 SR patients with a mean follow-up of 12.2 months. Although there was no difference between SR and IR patients in the development of postprocedural renal impairment (IR, 25.9%; SR, 29.9%; P ϭ .46) or postoperative CrCl (IR, 61.7 mL/min; SR, 64.9 mL/min; P ϭ .26), postoperative CrCl was significantly worse in both IR (69.3 to 61.7 mL/min, P Ͻ .01) and SR groups (71.7 to 64.9 mL/min, P Ͻ .03) compared with preoperative values. This amounted to an approximate 10% decrease in CrCl in both the IR and SR patients within the first year after EVAR.
It has been proposed that these findings likely result from the cumulative effect of repeated contrast exposures during routine graft surveillance. 15, 19 To limit this effect, the use of magnetic resonance angiography or duplex ultrasonography has been suggested as an alternative to CT angiography and should be considered, especially in those at high risk for developing contrast induced nephropathy. 8, 15, 19 Furthermore, for high-risk patients requiring repeated contrast studies, acetylcysteine 35 or sodium bicarbonate 36 alone or in combination have been shown to decrease the adverse consequences of contrast and should be used.
Despite progressive renal dysfunction in both groups as a whole, only 15 IR (10.2%) and six SR patients (7.6%) developed significant renal impairment, and in only one patient (0.7%) in the IR group was hemodialysis required. Furthermore, in those who developed renal impairment, there was no difference in contrast administration between the IR and SR groups (184 Ϯ 86 mL vs 130 Ϯ 56 mL, P ϭ .212). These data seem to confirm that there is no significant difference in the impact of SR fixation on renal function compared with IR fixation.
The incidence of adverse renal events, including progressive renal artery stenosis, renal stent placement, renal artery occlusion, or renal infarction, were uncommon in either group and were not statistically different between groups (Table III) . This is in contrast to the previous study by Bockler et al, 9 where a significant increase in infarction rate in patients receiving SR fixation vs IR fixation was noted. As they used a variety of grafts, it is difficult to determine why exactly they had such a high rate of renal infarction. Their report noted higher rates of renal infarction in balloon-expandable grafts, 9 which have been proposed as a risk factor for the development of renal complications, specifically renal infarction, and might be at least partly responsible for their findings. 8 Limitations of this study include it being a multicenter, nonrandomized study in which the analysis was performed in a retrospective manner. As a result, selection and reporting biases are likely to occur; however, the use of identical inclusion and exclusion criteria should limit this effect. Also, serum creatinine was used in this study as the marker of renal function as it is a readily obtainable value that has been used consistently when evaluating renal function after repair of abdominal aortic aneurysms. Because of the insensitivity of this method, an attempt to compensate for weight, gender, and age was made by calculating CrCl using the Cockcroft-Gault method, realizing this formula may overestimate glomerular filtration rate by 16%. 37 As both groups were treated similarly, however, the trends between groups and temporally should have been maintained despite using these measures.
Although direct measurements are more sensitive in monitoring renal function and include perfusion scintigraphy 34 or urinary creatinine clearance, they are expensive and difficult to obtain consistently in the trial setting and were not performed routinely. In addition, few renal events were detected, raising the possibility of lacking the sensitivity needed to detect a difference between groups and risking a type II error.
This study relied entirely on the use of CT angiography with reconstructed images to evaluate renal artery stenosis. The use of routine duplex ultrasonography scans to demonstrate flow disturbances has been suggested and may have allowed for more sensitive detection of flow-limiting stenosis not seen on CT imaging. [12] [13] [14] [15] Despite these limitations, however, this is the only study to date, to our knowledge, to evaluate the effects of suprarenal fixation on renal function by comparing grafts that are identical in every aspect except for fixation scheme. This should eliminate many of the differences due to graft design, materials, or deployment techniques, thus providing a more accurate measure of the renal effects from suprarenal fixation compared with infrarenal fixation than those previously published.
CONCLUSION
Suprarenal fixation appears to be comparable to infrarenal fixation and does not lead to a significant increase in acute renal events, renal impairment, or alterations in blood pressure. Patients undergoing aneurysm repair with either suprarenal or infrarenal fixation devices tend to have progressive renal dysfunction over time. Further studies will be required to determine what long-term effects suprarenal fixation may have on the progression of renal artery stenosis and renal function.
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